Primary resistance to crizotinib treatment in a non-small cell lung cancer patient with an EML4-ALK rearrangement: a case report
Crizotinib, a small molecular tyrosine kinase inhibitor, manifests dramatic responses in patients with non-small cell lung cancer with echinoderm microtubule associated protein like 4-anaplastic lymphoma kinase (EML4-ALK) rearrangements. ALK gene point mutation is the primary mechanism of acquired c...
Guardado en:
| Autores principales: | , , , , , |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
China Anti-Cancer Association
2018-06-01
|
| Colección: | Cancer Biology & Medicine |
| Materias: | |
| Acceso en línea: | http://www.cancerbiomed.org/index.php/cocr/article/view/1133 |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|